Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Statins protect from death from pneumonia

25.07.2005


Patients hospitalised because of pneumonia are at less risk of dying from the disease if they have been taking the widely used cholesterol-lowering drugs ’statins’ before hospital admission. These results, published today in the Open Access journal Respiratory Research, suggest another beneficial use of statins, which are prescribed to an increasing number of patients to prevent and treat high cholesterol, diabetes, heart disease and vascular disease.



Pneumonia is the seventh most common cause of death and the leading cause of death from infection in the USA, where it kills up to 40,000 people every year – those most at risk are very young children, elderly people and patients with underlying health problems such as AIDS or chronic obstructive pulmonary disease (CPOD). The disease is caused by viruses or bacteria, which are becoming resistant to the antibiotics used to treat bacterial pneumonia.

Eric Mortensen and colleagues, from the University of Texas Health Centre at San Antonio measured the risk of dying from pneumonia in patients admitted with pneumonia who were taking statins prior to their entry into hospital. They compared it with the risk of dying from the disease in pneumonia patients who were not taking statins. The authors used the Pneumonia Severity Index to rate the risk of dying within 30 days of admission to hospital in the two groups of patients. The results of their statistical analysis show that patients who were on a statin when they entered hospital were 2.8 times less likely to die than patients who were not on statins.


"Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality", write the authors.

More research is needed to explain the protective effect of statins on patients suffering from pneumonia. Statins act on the cholesterol-regulating enzyme HMG-CoA reductase, but they are also known to affect the immune system and this might explain their effect on pneumonia patients.

Juliette Savin | EurekAlert!
Further information:
http://www.biomedcentral.com

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>